BACKGROUND AND PURPOSE: Sympathetic nervous system (SNS) hyperactivity is characteristic of chronic heart failure (HF) and significantly worsens prognosis. The success of β-adrenoceptor antagonist (β-blockers) therapy in HF is primarily attributed to protection of the heart from the noxious effects of augmented catecholamine levels. β-Blockers have been shown to reduce SNS hyperactivity in HF, but the underlying molecular mechanisms are not understood. The GPCR kinase-2 (GRK2)-α(2) adrenoceptor-catecholamine production axis is up-regulated in the adrenal medulla during HF causing α(2) -adrenoceptor dysfunction and elevated catecholamine levels. Here, we sought to investigate if β-blocker treatment in HF could lower SNS activation by directly altering adrenal GRK2 levels. EXPERIMENTAL APPROACH: Four weeks after myocardial infarction-induced HF, adult rats were randomized to 10-week treatment with vehicle (HF/C) or bisoprolol (HF/B). Cardiac function and dimensions were measured. In heart and adrenal gland, GRK2 levels were assessed by RT-PCR and Western blotting and adrenoceptors studied with radioligand binding. Catecholamines and α(2) adrenoceptors in adrenal medulla chromaffin cell cultures were also measured. KEY RESULTS: Bisoprolol treatment ameliorated HF-related adverse cardiac remodelling and reduced plasma catecholamine levels, compared with HF/C rats. Bisoprolol also attenuated adrenal GRK2 overexpression as observed in HF/C rats and increased α(2) adrenoceptor density. In cultures of adrenal medulla chromaffin cells from all study groups, bisoprolol reversed HF-related α(2) adrenoceptor dysfunction. This effect was reversed by GRK2 overexpression. CONCLUSION AND IMPLICATIONS: Blockade of β-adrenoceptors normalized the adrenal α(2) adrenoceptor-catecholamine production axis by reducing GRK2 levels. This effect may contribute significantly to the decrease of HF-related sympathetic overdrive by β-blockers.
BACKGROUND AND PURPOSE: Sympathetic nervous system (SNS) hyperactivity is characteristic of chronic heart failure (HF) and significantly worsens prognosis. The success of β-adrenoceptor antagonist (β-blockers) therapy in HF is primarily attributed to protection of the heart from the noxious effects of augmented catecholamine levels. β-Blockers have been shown to reduce SNS hyperactivity in HF, but the underlying molecular mechanisms are not understood. The GPCR kinase-2 (GRK2)-α(2) adrenoceptor-catecholamine production axis is up-regulated in the adrenal medulla during HF causing α(2) -adrenoceptor dysfunction and elevated catecholamine levels. Here, we sought to investigate if β-blocker treatment in HF could lower SNS activation by directly altering adrenal GRK2 levels. EXPERIMENTAL APPROACH: Four weeks after myocardial infarction-induced HF, adult rats were randomized to 10-week treatment with vehicle (HF/C) or bisoprolol (HF/B). Cardiac function and dimensions were measured. In heart and adrenal gland, GRK2 levels were assessed by RT-PCR and Western blotting and adrenoceptors studied with radioligand binding. Catecholamines and α(2) adrenoceptors in adrenal medulla chromaffin cell cultures were also measured. KEY RESULTS:Bisoprolol treatment ameliorated HF-related adverse cardiac remodelling and reduced plasma catecholamine levels, compared with HF/C rats. Bisoprolol also attenuated adrenal GRK2 overexpression as observed in HF/C rats and increased α(2) adrenoceptor density. In cultures of adrenal medulla chromaffin cells from all study groups, bisoprolol reversed HF-related α(2) adrenoceptor dysfunction. This effect was reversed by GRK2 overexpression. CONCLUSION AND IMPLICATIONS: Blockade of β-adrenoceptors normalized the adrenal α(2) adrenoceptor-catecholamine production axis by reducing GRK2 levels. This effect may contribute significantly to the decrease of HF-related sympathetic overdrive by β-blockers.
Authors: Brian D Lowes; Edward M Gilbert; William T Abraham; Wayne A Minobe; Patti Larrabee; Debra Ferguson; Eugene E Wolfel; JoAnn Lindenfeld; Tatiana Tsvetkova; Alastair D Robertson; Robert A Quaife; Michael R Bristow Journal: N Engl J Med Date: 2002-05-02 Impact factor: 91.245
Authors: K Watanabe; Y Ohta; M Inoue; M Ma; M I Wahed; M Nakazawa; G Hasegawa; M Naito; K Fuse; M Ito; K Kato; H Hanawa; M Kodama; Y Aizawa Journal: J Cardiovasc Pharmacol Date: 2001-10 Impact factor: 3.105
Authors: Karl Swedberg; Michael R Bristow; Jay N Cohn; Henry Dargie; Matthias Straub; Curtis Wiltse; Theressa J Wright Journal: Circulation Date: 2002-04-16 Impact factor: 29.690
Authors: Martine Blanchet; Anique Ducharme; Normand Racine; Jean Lucien Rouleau; Jean Claude Tardif; Martin Juneau; Johanne Marquis; Lucie Larivée; Anil Nigam; Anick Fortier; Michel White Journal: Am J Cardiol Date: 2003-09-01 Impact factor: 2.778
Authors: Daniel Chikere Ali; Muhammad Naveed; Andrew Gordon; Fatima Majeed; Muhammad Saeed; Michael I Ogbuke; Muhammad Atif; Hafiz Muhammad Zubair; Li Changxing Journal: Heart Fail Rev Date: 2020-03 Impact factor: 4.214
Authors: Alessandro Cannavo; Giuseppe Rengo; Daniela Liccardo; Gennaro Pagano; Carmela Zincarelli; Maria Carmen De Angelis; Roberto Puglia; Elisa Di Pietro; Joseph E Rabinowitz; Maria Vittoria Barone; Plinio Cirillo; Bruno Trimarco; Timothy M Palmer; Nicola Ferrara; Walter J Koch; Dario Leosco; Antonio Rapacciuolo Journal: Circulation Date: 2013-08-22 Impact factor: 29.690